Marrow infiltrating lymphocytes - WindMIL Therapeutics
Alternative Names: MILs™ - NSCLC; Non gene-modified MILs - WindMIL TherapeuticsLatest Information Update: 12 Aug 2022
At a glance
- Originator WindMIL Therapeutics
- Developer Bristol-Myers Squibb; WindMIL Therapeutics
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I Haematological malignancies
- Phase 0 Solid tumours
- Preclinical Breast cancer; Glioblastoma; Head and neck cancer
Most Recent Events
- 02 Aug 2022 WindMIL Therapeutics and Bristol-Myers Squibb terminated its in a phase II trial in Non-small cell lung cancer (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA due to resourcing (Parenteral) (NCT04069936)
- 10 Feb 2022 Phase-0 for Solid tumours (Parenteral) as of february 2022 (WindMIL Therapeutics pipeline, February 2022)
- 10 Feb 2022 Phase-I clinical trials in Haematological malignancies (Parenteral) as of february 2022 (WindMIL Therapeutics pipeline, February 2022)